Neurocrine Biosciences Presents Two-Year Data on CRENESSITY for Congenital Adrenal Hyperplasia

Event summary

  • Neurocrine Biosciences will present two-year data on CRENESSITY (crinecerfont) for classic congenital adrenal hyperplasia (CAH) at ENDO 2026.
  • Data highlights sustained androgen control, glucocorticoid dose reduction, and improved patient-reported outcomes in both adult and pediatric populations.
  • Additional presentations include data on VYKAT XR (diazoxide choline) for Prader-Willi syndrome (PWS), including long-term extension findings.
  • CRENESSITY was approved by the FDA in December 2024 for the treatment of classic CAH.

The big picture

Neurocrine Biosciences is positioning CRENESSITY as a transformative treatment for classic CAH, addressing long-standing challenges with glucocorticoid therapy. The two-year data presented at ENDO 2026 could further solidify its market position in rare disease treatment. The company's focus on sustained androgen control and improved patient quality of life aligns with broader industry trends toward precision medicine and patient-centric outcomes.

What we're watching

Long-Term Efficacy
Whether CRENESSITY can sustain its observed benefits over extended periods and across broader patient populations.
Market Adoption
The pace at which CRENESSITY becomes the standard of care for classic CAH, given its potential to reduce glucocorticoid exposure.
Regulatory Expansion
How Neurocrine Biosciences will leverage these data to expand CRENESSITY's indications or explore new therapeutic areas.